
AI agents for pharmaceutical and medtech companies
Entrusting the repetitive tasks of medical, regulatory, market access, commercial and R&D teams to AI agents, under the control of your experts.
AI projects delivered
innovation projects overall
Who is it for? Pharmaceutical companies, biotechs and medtechs that want to entrust specific tasks to AI agents, with clear safeguards and human validation at every step.
An AI agent is a system that chains actions (reading a document, searching for information, drafting, calling a tool) to reach a goal, under human oversight. Where a conversational assistant answers a question, the agent carries out a task from start to finish and reports on what it has done. In a pharmaceutical or medtech company, it handles the repetitive steps of a process; the decision stays with a qualified person.
The Challenge
Medical, regulatory, market access, commercial and R&D teams spend a large share of their time searching for, compiling and formatting information: publications, dossiers, meeting reports, internal guidelines. These tasks lend themselves well to AI agents. Yet they take place within a strict framework: health data, regulated promotional information, pharmacovigilance, and now the AI Act.
The main risk is not technical. It comes from agents launched without a written scope, without human validation or traceability, producing content that nobody reviews. A useful agent is first and foremost a well-scoped agent.
Use cases by function
For each function: the task, what the agent does, and what stays with people.
Medical affairs
The task. Answering medical information requests and keeping up with the literature.
What the agent does. It searches validated documents and publications, drafts a response that cites its sources, and flags what it could not find.
What stays with people. Review by a qualified person, sending the response, and any question that concerns a patient.
Regulatory affairs
The task. Tracking changes in the texts and preparing dossier documents.
What the agent does. It monitors publications from the authorities, summarises the changes that affect your products and checks that a document follows the expected template.
What stays with people. Interpreting the texts, the regulatory strategy and signing the documents submitted to the authorities.
Market access
The task. Gathering the evidence and preparing assessment dossiers.
What the agent does. It lists the published studies, extracts the relevant data into a table and prepares a first draft of the value arguments, with each data point linked to its source.
What stays with people. The product positioning, health-economic modelling and discussions with the HAS.
Sales and marketing
The task. Preparing visits and content for healthcare professionals.
What the agent does. It prepares the physician’s profile before the visit (latest interactions, areas of interest, approved messages) and suggests content based on the approved messages.
What stays with people. The relationship with the healthcare professional, and the validation of any promotional content through the usual review process.
R&D
The task. Exploring the scientific literature and preparing study documents.
What the agent does. It summarises publications on a target or an indication, compares protocols and prepares first drafts of documents from your templates.
What stays with people. The scientific hypotheses, study design and any decision that affects the safety of participants.
Safeguards
AI Act. The European regulation on artificial intelligence (Regulation (EU) 2024/1689), amended in 2026 by the Digital Omnibus on AI (Regulation (EU) 2026/1744), sets obligations according to the risk level of each use. An agent that interacts with people must tell them they are dealing with an AI: this is the transparency obligation of Article 50. We classify each agent by risk level before building it.
Health data. Health data are sensitive data under the GDPR (Regulation (EU) 2016/679). An agent only accesses the data its task requires, pseudonymised or anonymised where possible. The French data protection authority, the CNIL, has published a recommendation on applying the GDPR to the development of AI systems (in French). In France, a provider that hosts health data on behalf of a third party must hold HDS certification, and the current standard requires hosting within the European Economic Area (French digital health agency, in French).
Human validation. Each agent has a written scope: what it does, what it never does, and when it hands over. Any content intended for external use (medical information, promotional information, documents submitted to the authorities) goes through the usual review process. For healthcare professionals, the French National Authority for Health (HAS) published its guide “First keys for using generative AI in healthcare” (in French) on 30 October 2025; its A.V.E.C. method (learn, verify, estimate, communicate) also gives medical teams a common basis.
Traceability. An agent must be able to account for what it has done: sources consulted, tools called, model version, person who validated. For medicines, the EMA adopted in September 2024 a reflection paper on the use of AI in the medicinal product lifecycle. Its approach is risk-based: the more AI influences a regulatory decision or patient safety, the stronger the requirements. The applicant or marketing authorisation holder remains responsible for the data, models and tools used.
Our Approach
We start from a real process, not from a technology. Our method has three phases.
Scoping. Choosing a specific task, describing how it is done today, writing the agent’s scope and classifying it by risk level under the AI Act.
Prototype. Building the agent with business teams, on their documents, in short cycles, and testing it on real cases before it goes live.
Deployment. Integrating the agent into existing tools, training teams, monitoring quality over time and adjusting the scope. The goal is not to deliver a tool, but to build lasting internal capability.
Across more than 40 AI projects, successful deployments share three traits: strong business sponsorship, data that is structured from the outset, and clear AI governance. This work extends our AI in Healthcare expertise, which covers AI strategy and governance.
What Digital Pharma Lab offers
- Custom AI agents. Copilot agents set up for your tasks, from simple to advanced: a ready-to-use agent, for example for visit preparation, or a suite of agents for one business line, with its governance. The scope is set with you during an initial scoping session: request a conversation.
- Virtual agent board. AI agents play your company’s functions (market access, medical, regulatory, sales and communication): ask one question, and each relevant function gives its view before you present a decision. The page is in French.
- AI Compass. Our AI strategy and governance platform: AI tool inventory, risk-level classification of your systems, roadmap and monitoring.
- AI playbooks. Six free playbooks, one for each company type and size: AI usage policy, European and French regulatory framework, role sheets with ready-to-use prompts.
- Health and medicines glossary. Definitions of AI agent, LLM and RAG, among the sector’s terms and acronyms. The glossary is in French.
- Generative AI and the health industry training. One day to understand the fundamentals of generative AI, test concrete tools and design a use case tailored to your environment.
To discuss your first agent, contact us.
Official sources
The reference texts and guidance this page is based on.
- EUR-Lex Regulation (EU) 2024/1689 on artificial intelligence (AI Act) (opens in a new tab)
- EUR-Lex Regulation (EU) 2016/679, General Data Protection Regulation (GDPR) (opens in a new tab)
- EMA Reflection paper on the use of artificial intelligence in the medicinal product lifecycle (2024) (opens in a new tab)
Frequently asked questions
What is an AI agent?
An AI agent is a system built on an AI model that chains actions to reach a goal: reading a document, searching for information, drafting, calling a tool. Unlike an assistant that answers a question, it carries out a task from start to finish. In a pharmaceutical company, it works under human oversight: a qualified person sets its scope and validates what it produces.
Which tasks can an AI agent take on in a pharmaceutical company?
Repetitive, well-defined tasks whose output can be checked: drafting a medical information response from validated documents, tracking changes in regulatory texts, gathering the publications needed for a market access dossier, preparing a visit to a healthcare professional or summarising the scientific literature. Medical, regulatory and commercial decisions stay with your teams.
What does the AI Act say about AI agents?
The AI Act, the European regulation on artificial intelligence amended in 2026 by the Digital Omnibus, sets obligations according to the risk level of each use. An agent that interacts with people must tell them they are dealing with an AI: this is the transparency obligation of Article 50. An agent that screens job applications, on the other hand, falls under high-risk systems. Classification is therefore done use by use.
How do you protect the health data an agent uses?
Health data are sensitive data under the GDPR. The agent only accesses the data its task requires, pseudonymised or anonymised where possible, and the DPO approves the use before launch. In France, a provider that hosts health data on behalf of a third party must hold HDS certification: check this point and the hosting location before choosing a tool.
How do you start an AI agent project with Digital Pharma Lab?
We start from a specific task and a real process. An initial scoping phase sets the agent’s scope, its risk level and what stays with people. We then build a prototype with your teams, on your documents, before deploying it in your tools and training users. For a first conversation, write to us or book a slot from the contact page.